ATE145820T1 - Verzögerte freigabe-matrix für arzneimittel - Google Patents

Verzögerte freigabe-matrix für arzneimittel

Info

Publication number
ATE145820T1
ATE145820T1 AT92106509T AT92106509T ATE145820T1 AT E145820 T1 ATE145820 T1 AT E145820T1 AT 92106509 T AT92106509 T AT 92106509T AT 92106509 T AT92106509 T AT 92106509T AT E145820 T1 ATE145820 T1 AT E145820T1
Authority
AT
Austria
Prior art keywords
release matrix
delayed release
medicinal products
matrix
composition
Prior art date
Application number
AT92106509T
Other languages
English (en)
Inventor
Thinnayam N Krishnamurthy
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE145820T1 publication Critical patent/ATE145820T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92106509T 1991-09-11 1992-04-15 Verzögerte freigabe-matrix für arzneimittel ATE145820T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/758,883 US5215758A (en) 1991-09-11 1991-09-11 Controlled release matrix suppository for pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE145820T1 true ATE145820T1 (de) 1996-12-15

Family

ID=25053475

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95113543T ATE187887T1 (de) 1991-09-11 1992-04-15 Verzögerte freigabe matrix für arzneimittel
AT92106509T ATE145820T1 (de) 1991-09-11 1992-04-15 Verzögerte freigabe-matrix für arzneimittel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95113543T ATE187887T1 (de) 1991-09-11 1992-04-15 Verzögerte freigabe matrix für arzneimittel

Country Status (13)

Country Link
US (2) US5215758A (de)
EP (2) EP0698389B1 (de)
JP (2) JP3034125B2 (de)
KR (2) KR100203339B1 (de)
AT (2) ATE187887T1 (de)
AU (1) AU653048B2 (de)
CA (1) CA2065210C (de)
DE (2) DE69215612T2 (de)
DK (2) DK0698389T3 (de)
ES (2) ES2139798T3 (de)
GR (1) GR3022572T3 (de)
IL (2) IL101758A (de)
ZA (1) ZA923417B (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
CA2141459A1 (en) * 1992-07-31 1994-02-17 Richard Yu Controlled release implants
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5891471A (en) 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5554379A (en) * 1994-06-20 1996-09-10 Kv Pharmaceutical Company Long acting GI and esophageal protectant
US5670163A (en) * 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
US5554380A (en) * 1994-08-04 1996-09-10 Kv Pharmaceutical Company Bioadhesive pharmaceutical delivery system
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
KR970064596A (ko) * 1996-03-21 1997-10-13 이우용 직장투여용 치질치료제 조성물
GB9710767D0 (en) * 1996-06-26 1997-07-23 On Ninh Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same
JP3148256B2 (ja) 1996-07-08 2001-03-19 エドワード メンデル カンパニー．，インコーポレーテッド 高用量難溶性薬物用持続放出マトリックス
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US5989571A (en) * 1997-07-23 1999-11-23 Millenium Pharmaceutical Technologies, Inc. Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9816899D0 (en) 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
ES2253851T3 (es) 1998-08-07 2006-06-01 Curis, Inc. Composicion farmaceutica estable de proteinas hedgehog y uso de la misma.
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
AU6283299A (en) * 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
HK1042427A1 (zh) * 1999-09-30 2002-08-16 Penwest Pharmaceuticals Co. 用於高溶度药物的持续释放基质方法
CA2400578C (en) 2000-02-08 2007-01-02 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US6720356B2 (en) * 2001-04-20 2004-04-13 Spencer Feldman Magnesium di-potassium EDTA complex and method of administration
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
EP1387673B1 (de) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Opioid enthaltende arzneiform gegen missbrauch
KR20030034171A (ko) * 2001-07-06 2003-05-01 엔도 파마슈티걸즈, 인크. 옥시모르폰 제어 방출 제형
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
LT2425821T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
SI1551372T1 (en) 2002-09-20 2018-08-31 Alpharma Pharmaceuticals Llc SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
JP4808405B2 (ja) * 2002-11-26 2011-11-02 ホ−レンベック ギャリ− ア−ル 高度に水溶性の電解質薬剤のための水性徐放性ドラッグデリバリーシステム
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
SI1663229T1 (sl) 2003-09-25 2010-08-31 Euro Celtique Sa Farmacevtske kombinacije hidrokodona in naltreksona
MXPA06003392A (es) 2003-09-25 2006-06-08 Euro Celtique Sa Combinacion farmaceutica de hidrocodona y naltrexona.
TWI365880B (en) * 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
US9308164B2 (en) 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US20070082050A1 (en) * 2005-05-31 2007-04-12 Cherukuri S R Modified release formulations of antihypertensive drugs
KR100730321B1 (ko) 2005-09-30 2007-06-19 한국콜마 주식회사 패치형태의 리프팅용 2제형 화장료 조성물과 이의 제조방법및 사용방법
SE530184C2 (sv) 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
AU2006334020B2 (en) * 2005-12-30 2012-07-05 Mor Research Applications Ltd. Device and method for treating the anal sphincter
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070286884A1 (en) * 2006-06-13 2007-12-13 Xylos Corporation Implantable microbial cellulose materials for hard tissue repair and regeneration
SI2484346T1 (sl) 2006-06-19 2017-05-31 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
CA2671197A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US20100266645A1 (en) * 2007-12-17 2010-10-21 Alfred Liang Pharmaceutical compositions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
SI2317991T1 (sl) * 2008-07-07 2017-09-29 Euro-Celtique S.A. Uporaba opioidnih antagonistov za zdravljenje retencije urina
PT2349250T (pt) * 2008-10-31 2017-07-25 Lipid Pharmaceuticals Ehf Ácidos gordos para uso como um medicamento
PL2405915T3 (pl) 2009-03-10 2019-05-31 Euro Celtique Sa Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
WO2010146591A2 (en) 2009-06-18 2010-12-23 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20130190299A1 (en) 2010-06-30 2013-07-25 Victoria Link Ltd. Methods and compositions for treatment of multiple sclerosis
PL2826467T3 (pl) 2010-12-22 2018-01-31 Purdue Pharma Lp Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EA028092B1 (ru) 2012-07-16 2017-10-31 Родс Текнолоджис Способ усовершенствованного синтеза опиоидов
NZ628695A (en) 2012-07-16 2016-02-26 Rhodes Technologies Process for improved opioid synthesis
CN102823585B (zh) * 2012-08-28 2014-06-25 中国农业科学院农业环境与可持续发展研究所 一种水溶性农药缓控释制剂及其制备方法
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9127008B2 (en) 2013-03-15 2015-09-08 Johnson Matthey Public Limited Company Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain
KR20160034352A (ko) 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
EP3027622B8 (de) 2013-08-02 2019-06-12 Johnson Matthey Public Limited Company Verfahren zur herstellung von oxymorphon
EP3082770A1 (de) * 2013-12-20 2016-10-26 Disphar International B.V. Trockeneinlaufprodukt
AU2015207733A1 (en) 2014-01-15 2016-07-14 Rhodes Technologies Process for improved oxycodone synthesis
MX379406B (es) 2014-01-15 2025-03-11 Rhodes Tech Proceso para la síntesis mejorada de oximorfona.
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9145420B1 (en) 2015-03-27 2015-09-29 Johnson Matthey Public Limited Company Crystalline forms of morphine sulfate
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629393A (en) * 1969-09-11 1971-12-21 Nikken Chemicals Co Ltd Release-sustaining-tablet
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
JPH0684296B2 (ja) * 1987-12-21 1994-10-26 花王株式会社 多層坐剤
US5102666A (en) * 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5110605A (en) * 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method

Also Published As

Publication number Publication date
DK0531611T3 (da) 1997-05-26
DE69230475D1 (de) 2000-01-27
ES2139798T3 (es) 2000-02-16
ES2097826T3 (es) 1997-04-16
IL117356A0 (en) 1996-07-23
AU653048B2 (en) 1994-09-15
EP0698389A1 (de) 1996-02-28
US5508043A (en) 1996-04-16
IL101758A (en) 1996-12-05
DE69230475T2 (de) 2000-07-13
EP0531611A1 (de) 1993-03-17
ZA923417B (en) 1993-01-27
US5215758A (en) 1993-06-01
IL117356A (en) 2000-08-31
DE69215612D1 (de) 1997-01-16
KR100225493B1 (en) 1999-10-15
JP3624123B2 (ja) 2005-03-02
GR3022572T3 (en) 1997-05-31
JP3034125B2 (ja) 2000-04-17
KR930005616A (ko) 1993-04-20
ATE187887T1 (de) 2000-01-15
DE69215612T2 (de) 1997-05-15
CA2065210C (en) 2000-08-29
IL101758A0 (en) 1992-12-30
EP0531611B1 (de) 1996-12-04
EP0698389B1 (de) 1999-12-22
JPH05148159A (ja) 1993-06-15
CA2065210A1 (en) 1993-03-12
AU2107392A (en) 1993-03-18
KR100203339B1 (ko) 1999-06-15
JP2000136149A (ja) 2000-05-16
DK0698389T3 (da) 2000-05-01

Similar Documents

Publication Publication Date Title
ATE187887T1 (de) Verzögerte freigabe matrix für arzneimittel
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
NO944470D0 (no) Tablettkjerner med umiddelbar frigivelse av ulöselige legemidler og med belegg med forsinket frigivelse
KR870005637A (ko) 약물 데포
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
PT80157B (en) Methods of treating viral diseases with pyridazinamines anti-virally active pyridazinamines
DE69034070D1 (de) Racemisches Huperzin A
SE8800025D0 (sv) Bioadhesive suppository pharmaceutical preparations
EP0661052A4 (de) Pharmazeutische zubereitung, die eine prostaglandinverbindung zur rektalen oder vaginalen verabreichung enthält.
DK4481A (da) Hydroxyalkylstivelse som laegemiddelbaerer
FR2674754B1 (fr) Composition medicamenteuse micronisee.
SE8703889L (sv) Farmaceutiska kompositioner med fordrojd frigoring
ES2078256T3 (es) Formula farmaceutica para uso topico que contiene diclofenaco sodico.
DE69232014D1 (de) Amethocain enthaltende Arzneimittel
IT7823016A0 (it) Composto farmaceutico di migliorata attivita' mucolitica e fluidificante delle secrezioni mucose.
SE8704240D0 (sv) Analgesic preparations
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
KR920000316A (ko) 젬피브로질 제제
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
KR930700100A (ko) 수의학적 치료
GB1454389A (en) Nasal decongestants nasal decongestants
MY110416A (en) Composition for the treatment of schizophrenia.
UA885A1 (uk) Засiб для лiкуваhhя шлуhково-кишкових захворюваhь з озhаками дiареї
MX174642B (es) Formulaciones farmaceuticas
IL37277A (en) Pharmacologically active n-piperidino-n'-(4-(5-methylpyrazine carboxamido)ethyl)benzene sulphonyl urea derivatives and process for their preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification